Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-06-30 was 0.00%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-19 | |||
| 2024-12-31 | 0.00% 10-K · filed 2025-03-31 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-13 | |||
| 2022-12-31 | 0.00% 10-K/A · filed 2024-05-14 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-31 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-04-07 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-14 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2020-06-18 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-25 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2019-05-16 | |||
| 2018-12-31 | 0.00% 10-K · filed 2020-04-29 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | 0.00% 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-29 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-15 | |||
| 2016-12-31 | 0.00% 10-K · filed 2018-04-02 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2016-11-17 | |||
| 2016-06-30 | 0.00% 10-Q · filed 2016-08-15 | |||
| 2016-03-31 | 0.00% 10-Q · filed 2016-07-25 | |||
| 2015-12-31 | 0.00% 8-K/A · filed 2016-07-12 | |||
| 2014-12-31 | 0.00% 8-K/A · filed 2016-07-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |